Sintx Technologies (NASDAQ:SINT) Given New $12.00 Price Target at Ascendiant Capital Markets

Sintx Technologies (NASDAQ:SINT) had its target price decreased by Ascendiant Capital Markets from $16.00 to $12.00 in a research note issued to investors on Wednesday morning,Benzinga reports. Ascendiant Capital Markets currently has a buy rating on the stock.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Sintx Technologies in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $12.00.

Sintx Technologies Stock Up 1.5%

SINT stock opened at $2.70 on Wednesday. Sintx Technologies has a 12 month low of $1.71 and a 12 month high of $6.78. The firm has a market cap of $11.12 million, a P/E ratio of -0.48 and a beta of 0.66. The company’s 50-day moving average price is $2.80 and its two-hundred day moving average price is $3.42.

Institutional Investors Weigh In On Sintx Technologies

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC grew its holdings in Sintx Technologies by 33.5% during the 2nd quarter. Geode Capital Management LLC now owns 15,339 shares of the company’s stock worth $49,000 after acquiring an additional 3,848 shares during the last quarter. Veracity Capital LLC grew its holdings in Sintx Technologies by 10.3% during the 3rd quarter. Veracity Capital LLC now owns 79,928 shares of the company’s stock worth $327,000 after acquiring an additional 7,464 shares during the last quarter. Finally, Virtus Wealth Solutions LLC bought a new stake in Sintx Technologies during the 3rd quarter worth approximately $388,000. Institutional investors own 18.38% of the company’s stock.

Sintx Technologies Company Profile

Sintx Technologies, Inc (NASDAQ: SINT) is a medical materials company specializing in the development and manufacture of silicon nitride-based biomaterials for surgical and implantable medical devices. Its proprietary silicon nitride ceramic combines mechanical strength, biocompatibility and intrinsic antimicrobial properties, positioning it as an alternative to traditional metal and polymer implant materials. Sintx’s primary focus is on applications in spinal fusion, trauma fixation and dental implantology, where device performance and long-term biological response are critical.

The company’s core product offerings include silicon nitride powders for advanced implant fabrication and finished implantable components designed for interbody spinal fusion cages, spinal fixation hardware and trauma plates and screws.